Philippine Health Research Registry
Display Options
Results List
Results 1 - 6 of 6 Adonis Guancia, MD research(es)

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Ongoing
Project Description:
The Sponsor plans to conduct the Phase III study prior to the completion of the Phase I study because the similarity in quality and in vivo behavior between SB3 and Herceptin® has already been demonstrated through extensive similarity exercises including physicochemical, biological characterisation studies, in vitro studies and in vivo non-clinica... [read more]
Project Status:
Ongoing
Project Description:
This is an open-label, randomized, parallel group Phase 2A/2B study to evaluate the clinical activity of ASLAN001 in combination with capecitabine compared with lapatinib in combination with capecitabine in patients with human epidermal growth factor receptor (HER) 2 positive metastatic breast cancer that has failed on prior trastuzumab therapy.  ... [read more]
Project Status:
Ongoing
Project Description:
This is a Phase III, randomized, double-blind, multicenter, active comparator, parallel two-arm trial to compare BI 695502 plus paclitaxel and carboplatin (Arm B) versus US-licensed Avastin® plus paclitaxel and carboplatin (Arm A).Duration: 13 MonthsObjectives: Primary objective:The primary objective of this trial is to establish statistical equiv... [read more]
Project Status:
Ongoing
Project Description:
This is a phase 3, multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy, safety, and immunogenicity of SAIT101 versus MabThera® in asymptomatic patients with low tumor burden follicular lymphoma. This study will take place globally across approximately 180 study sites in order to randomize approximately 308 patient... [read more]
Project Status:
Ongoing
Project Description:
This is a multinational, randomized, multicenter, double-blind, placebo-controlled, Phase 3 study in patients with histologically or cytologically confirmed advanced gastric or GEJ adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine. Approximately 450 patients will be randomized on a 2:1 ratio to... [read more]
Project Status:
Pending
Project Description:
To assess the safety and efficacy of REGN2810 as first-line treatment in patients with advanced or metastatic NSCLC whose tumors express PD-L1.